- Open Access
Effects of low-dose aspirin in subjects with dyslipidemia
© The Author(s). 2016
- Received: 28 April 2016
- Accepted: 11 June 2016
- Published: 16 June 2016
To evaluate the efficacy and safety of aspirin usage for coronary heart disease (CHD) primary prevention in patients with dyslipidemia.
A cross-sectional study was conducted to enrolled subjects with documented dyslipidemia. A total of 202 patients with dyslipidemia were recruited and 138 were undergone aspirin treatment before this indexed admission and 64 had never been treated with aspirin. All subjects were undergone coronary angiography to diagnoses CHD. Clinical characteristics were collected and comparisons were performed between subjects with aspirin and subjects without aspirin therapy. Logistic regression analysis was conducted to assess the relation between aspirin and incident CHD and bleeding events.
Compared to those with aspirin therapy, CHD incidence was significantly higher in subjects without aspirin therapy (23.4 % versus 18.1 %, P < 0.05). Five patients in the aspirin group had gastrointestinal bleeding and no bleeding event was occurred in subjects without aspirin therapy. Subjects with aspirin therapy had higher rate of previous helicobacter pylori (HP) infection (8.7 % versus 4.7 %, P < 0.05). Compared to subjects without CHD, subjects with CHD were older, had higher frequencies of males and smokers, had higher heart rate, serum LDL cholesterol, Lp(a) and Hs-CRP levels. Percentages of subjects with hypertension, diabetes, gastrointestinal bleeding, and HP infection were also considerably higher in CHD group (P < 0.05 for all comparison). Logistic regression analysis revealed that aspirin was associated with reduced incidence of CHD, with odds ratio (OR) of 0.85 (95 % confidence interval (CI): 0.80-0.94, P < 0.05). Regarding safety endpoint, gastrointestinal bleeding risk associated with aspirin was attenuated to nonsignificant after adjusting for HP infection, with OR of 1.16 (95 % CI: 0.99-1.52, P = 0.178).
Aspirin is beneficial for reducing incident CHD, while modestly increases gastrointestinal bleeding risk. Screening subjects with previous HP infection may avoid aspirin-related gastrointestinal bleeding.
- Atherosclerotic cardiovascular diseases
- Primary prevention
The effects of aspirin on secondary prevention of atherosclerotic cardiovascular diseases (ASCVD) have been consistently demonstrated by previous clinical studies [1, 2]. Nonetheless, the efficacies of aspirin on ASCVD primary prevention are conflicting [3–7]. In addition, aspirin may increase bleeding risks such as incident intracranial hemorrhage and gastrointestinal bleeding [1, 8]. Therefore, it is clinically relevant and important to balance the risk and benefit of aspirin prescription for ASCVD primary prevention.
Dyslipidemia is a major risk factor of ASCVD , and increased serum level of low density lipoprotein (LDL) cholesterol is associated with higher incidence and prevalence of coronary heart disease (CHD) and ischemic stroke [10, 11]. Statins has been broadly used for lowering serum LDL cholesterol level, which in turn reduces cardiovascular events [10, 12, 13]. Nonetheless, whether aspirin could decrease cardiovascular risk in subjects with dyslipidemia is uncertain, and the data on the efficacy of low-dose, enteric-coated and once-daily aspirin on ASCVD primary prevention in Chinese population is also limited. Thus this, we conducted a cross-sectional research to explore whether aspirin could reduce the incidence of CHD in subjects with documented dyslipidemia. Moreover, bleeding events presumably associated with aspirin use would also be evaluated. We hoped that data from present study would shed lights for future randomized controlled trials in investigating whether aspirin prescription could confer beneficial effects on ASCVD primary prevention in subjects with dyslipidemia.
Studied subjects enrollment
Studied subjects were consecutively enrolled with a cross-sectional design from in-patient department and all subjects were diagnosed with dyslipidemia based on either serum lipid profiles measurement, self-report or statins treatment. Informed consent was obtained and present study was approved by participating hospital ethnic committee (GRH20150814). Study inclusion criteria were as follow: all enrolled subjects had not been diagnosed with CHD previously and were undergone coronary angiography in present indexed admission. Exclusion criteria were those currently treating with anti-coagulatory agents (e.g. warfarin) or other anti-platelet drugs (e.g. clopidogrel) were excluded. In brief, diameter of coronary artery which is equal to or more than 70 % stenosis of adjacent proximal segment is diagnosed with CHD as reviewed by two independent investigators. Studied subjects were divided into two groups in terms of with and without CHD and between-group differences were conducted. In addition, studied subjects were also divided into with and without aspirin therapy groups and between-group differences were also performed.
Clinical characteristics collection
Demographic data including gender, age, and smoking status were extracted from in-patient medical document. Anthropometric parameters collections including systolic/diastolic blood pressure (SBP/DBP) at sitting, heart rate (HR) at rest, waist and hip circumferences using for calculating waist-hip ratio were performed by two experienced investigators. Laboratory examination results including total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL) cholesterol, LDL cholesterol, lipoprotein(a) (Lp(a)), apolipoprotein A1 (apoA1), apolipoprotein B (apoB), fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) were measured by using electrochemical method and high sensitivity C-reactive protein (Hs-CRP) was measured by using immunity transmission turbidity in our central laboratory. Medical histories including hypertension, diabetes, previous helicobactor pylori (HP) infection, intracranial hemorrhage or gastrointestinal bleeding presumably related to aspirin use were recorded in case report form. In brief, diagnosis of hypertension or diabetes were based on self-report, treating with anti-hypertensive or anti-diabetic medications, or measurements of indexes were higher than normal range as recommended by guideline recommendations [14, 15], respectively. Medicines use such as aspirin, statins, anti-hypertensive and anti-diabetes drugs were also recorded in case report form and underwent re-check by two independent investigators.
The efficacy endpoints of present study were to evaluate whether aspirin could reduce the incidence of CHD in subjects with documented dyslipidemia; and the safety endpoints were to assess whether low-dose, enteric-coated and once-daily aspirin would increase bleeding risks.
Continuous variables are presented with mean ± SD and categorical variables are presented with the number (percentages). Statistical significance of differences is analyzed using student t-test or Mann-Whitney U test for continuous variables and the chi-square or Fisher exact test for categorical variables. Logistic regression analysis was applied to calculate odds ratio (OD) and its’ associated 95 % confidence intervals (CI) of aspirin on incident CHD and bleeding events. Statistical analysis is computed using SPSS 18.0 (SPSS Inc, Chicago, IL). All of the statistical tests were two-sided and considered statistically significant if P < 0.05.
Clinical characteristics of subjects with and without aspirin therapy
Comparisons between subjects with and without aspirin therapy
With aspirin (n = 138)
Without aspirin (n = 64)
53.2 ± 8.4
51.7 ± 6.9
135.7 ± 17.4
131.3 ± 12.8
71.4 ± 10.3
70.6 ± 11.6
75.5 ± 13.2
72.6 ± 13.1
0.89 ± 0.03
0.88 ± 0.05
5.13 ± 0.24
5.11 ± 0.22
1.54 ± 0.32
1.57 ± 0.30
3.36 ± 0.41
3.40 ± 0.36
0.93 ± 0.06
0.92 ± 0.06
238.96 ± 26.45
244.35 ± 33.15
1.06 ± 0.33
1.05 ± 0.29
1.10 ± 0.26
1.11 ± 0.30
5.3 ± 0.6
5.4 ± 0.5
5.9 ± 0.8
5.8 ± 0.6
10.7 ± 3.5
11.4 ± 3.2
Intracranial hemorrhage (%)
Gastrointestinal bleeding (%)
HP infection (%)
Clinical characteristics of subjects with and without CHD
Comparisons between subjects with and without CHD
CHD(n = 40)
Without CHD(n = 162)
55.4 ± 8.7*
51.2 ± 7.3
134.2 ± 14.5
132.6 ± 16.3
73.5 ± 10.1
71.4 ± 8.6
77.3 ± 8.0*
71.4 ± 6.6
0.90 ± 0.04
0.88 ± 0.05
5.28 ± 0.23
5.04 ± 0.22
1.66 ± 0.30
1.59 ± 0.37
3.49 ± 0.44*
3.20 ± 0.38
0.89 ± 0.17
0.92 ± 0.20
258.56 ± 30.86*
227.16 ± 24.43
1.04 ± 0.27
1.07 ± 0.22
1.15 ± 0.33
1.10 ± 0.29
5.5 ± 0.5
5.2 ± 0.6
5.9 ± 0.7
5.6 ± 0.5
13.4 ± 3.8*
10.7 ± 3.1
Intracranial hemorrhage (%)
Gastrointestinal bleeding (%)
HP infection (%)
Logistic regression analysis
Odds ratio of CHD and gastrointestinal bleeding in subjects with aspirin
With Aspirin (n = 138)
OR (95 % CI)
CHD, n (%)
Gastrointestinal bleeding, n (%)
Our preliminary data show that aspirin may be beneficial for decreasing incidence of CHD as documented by coronary angiography in subjects with dyslipidemia. Nonetheless, aspirin may also slightly increase gastrointestinal bleeding risk, especially in subjects with previous HP infection which deserves further investigation.
Aspirin now has been broadly used for ASCVD secondary prevention owing to its compelling evidence on improving cardiovascular outcomes . Nonetheless, data from primary prevention studies are controversial. In addition, aspirin therapy may increase bleeding risk and the major mechanisms are twofold . On the one hand, aspirin has effect on inhibiting cyclooxygenase thereby reducing platelet activation and adhesion. On the other hand, aspirin also has unwanted effect with respect to causing gastritis or gastric ulceration. Therefore, it should be cautious to balance the risk and benefit of prescribing aspirin before more solid evidence is available to demonstrate aspirin should be applied to subjects with ASCVD risk factors such as dyslipidemia.
We performed a cross-sectional research to investigate the relation between aspirin use and incidence of CHD as diagnosed by indexed coronary angiography. All our recruited subjects were diagnosed with dyslipidemia and more than 90 % was treated with statins. Results showed that after fully adjusting for potential confounding covariates, aspirin therapy was beneficial for reducing the incidence of CHD. However, the data from the Japanese Primary Prevention Project (JPPP) trial showed that aspirin therapy was not beneficial for reducing composite cardiovascular outcomes including nonfatal ischemic stroke, myocardial infarction and vascular death . There were several differences between our present study and the JPPP trial. First of all, the differences in studied design and ethnic group might largely account for these discrepancies. Second, we only investigated the effect of aspirin on CHD incidence while the JPPP trial additionally included ischemic stroke and vascular death as efficacy endpoints. It might be possible that aspirin has different effects on coronary artery and cerebral vessels, given the heterogeneity of mechanisms underlying cerebrovascular ischemia . Third, subjects in our present study were much younger than those in the JPPP trial, and aging might offset the potential benefits of aspirin therapy . Moreover, only a minority of subjects in our present study had co-morbidities such as hypertension and diabetes, which indicated that subjects in our present study were at relatively lower ASCVD risk compared to those in the JPPP trial. Furthermore, in another study investigating the effect of low-dose aspirin to prevent cardiovascular events in subjects with type 2 diabetes mellitus, Hisao and colleagues reported that on cardiovascular benefits were found . In a large meta-analysis, it was also revealed that aspirin for primary prevention, the cardiovascular benefit is uncertain. However, it might increase bleeding risk . Likewise, different study design and populations should largely be accounted for these discrepancies. In addition, with respect to our present findings, we considered that the benefit of aspirin for ASCVD primary prevention might be possible for a specific population but not the whole general population.
We further evaluated the incidence of bleeding events presumably associated with aspirin therapy. We mainly included intracranial hemorrhage and gastrointestinal bleeding as safety endpoints because these two adverse events were accounted for a vast majority of aspirin-related bleeding complications. Based on self-report, 5 cases of gastrointestinal bleeding presumably associated with aspirin therapy were identified and after initially adjusting for potential confounding factors, aspirin therapy appeared to increase gastrointestinal bleeding risk. Nonetheless, bleeding risk associated with aspirin therapy was attenuated to nonsignificant after additionally adjusting for HP infection. As is well known that HP infection increases the incidence of gastric and duodenal ulceration [19, 20], and the prevalence of HP infection in China is much higher than the other developed countries . Therefore, it was conceivable that subjects with HP infection in our current study might have occult gastrointestinal ulceration which exposed them at higher risk of gastrointestinal bleeding. These findings indicated that screening for HP infection might help reduce potential bleeding risk associated with aspirin therapy. In addition, smoking may also increase bleeding risk in relation to its effects on impairing coagulatory system although since no significant between-group difference in smoking rate was observed.
Comparisons between subjects with and without CHD revealed that subjects with CHD might at increased risk of gastrointestinal bleeding. For example, subjects with CHD were with male predominant, older, higher percentages of smoking, diabetes and HP infection, all of which were significant contributors of gastrointestinal bleeding. These findings might indicate that subjects at increased risk of CHD might also have a higher risk of gastrointestinal bleeding concomitantly.
There were several limitations of our current study. First of all, this was a cross-sectional research and the results from present study could not be used to conclude a causal relationship. Rather, present study might provide pilot data for future randomized perspective study to explore the effect of aspirin for CHD primary prevention. Second, we did not include ischemic stroke as an efficacy outcome because we did not have solid evidence to diagnose ischemic stroke in the absence of compute tomography scan. Owing to a high prevalence and incidence of ischemic stroke in Chinese population, it is clinically relevant to include ischemic stroke as an efficacy endpoint in future study. Third, the diagnoses of gastrointestinal bleeding and HP infection were based on self-report and therefore, the accuracy of the safety endpoint evaluation might be somewhat compromised. However, we had enquired both the patients’ immediate relative and charged physicians in other hospitals. Therefore, we considered that the possibility of diagnostic inaccuracy was small. Last but not the least, a small sample size of present study was not adequately powered to detect potential between-group differences.
Our current study shows that in subjects with dyslipidemia, low-dose, enteric-coated, once-daily aspirin is beneficial for reducing the incidence of CHD while only slightly increase gastrointestinal bleeding risk.
We appreciate very much for the help Dr. Huocheng Liao offered to us.
GL, JC and YX performed this study, GL performed statistical analyses, and YX designed this study and wrote this article. All authors read and approved the final manuscript.
The authors declare that they have no competing interest.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60.View ArticleGoogle Scholar
- Rodes-Cabau J, Horlick E, Ibrahim R, Cheema AN, Labinaz M, Nadeem N, Osten M, Cote M, Marsal JR, Rivest D, Marrero A, Houde C. Effect of clopidogrel and aspirin vs aspirin alone on migraine headaches after transcatheter atrial septal defect closure: The canoa randomized clinical trial. Jama. 2015;314:2147–54.View ArticlePubMedGoogle Scholar
- Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, Sugawara M, Ando K, Murata M, Yokoyama K, Ishizuka N. Low-dose aspirin for primary prevention of cardiovascular events in japanese patients 60 years or older with atherosclerotic risk factors: A randomized clinical trial. Jama. 2014;312:2510–20.View ArticlePubMedGoogle Scholar
- Jonsson B, Hansson L, Stalhammar NO. Health economics in the hypertension optimal treatment (hot) study: Costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. J Intern Med. 2003;253:472–80.View ArticlePubMedGoogle Scholar
- Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y. Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial I. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. Jama. 2008;300:2134–41.View ArticlePubMedGoogle Scholar
- Final report on the aspirin component of the ongoing physicians' health study. Steering committee of the physicians' health study research group. N Engl J Med. 1989;321:129–35.View ArticleGoogle Scholar
- Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293–304.View ArticlePubMedGoogle Scholar
- Wu IC, Lin MY, Yu FJ, Hsieh HM, Chiu KF, Wu MT. A short-term effect of low-dose aspirin on major hemorrhagic risks in primary prevention: A case-crossover design. PLoS One. 2014;9:e98326.View ArticlePubMedPubMed CentralGoogle Scholar
- Liao PJ, Xie RB, Yin RX, Wei DX, Huang J, Huang F, Li H, Lin WX, Wu JZ, Pan SL. Serum lipid profiles, the prevalence of dyslipidemia and the risk factors in two isolated chinese minorities. Int J Clin Exp Med. 2015;8:19200–11.PubMedPubMed CentralGoogle Scholar
- Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto Jr AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of afcaps/texcaps. Air force/texas coronary atherosclerosis prevention study. Jama. 1998;279:1615–22.View ArticlePubMedGoogle Scholar
- Watt J, Kennedy S, Ahmed N, Hayhurst J, McClure JD, Berry C, Wadsworth RM, Oldroyd KG. The relationship between oxidised ldl, endothelial progenitor cells and coronary endothelial function in patients with chd. Open Heart. 2016;3:e000342.View ArticlePubMedPubMed CentralGoogle Scholar
- Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, Shui A, McCabe CH, Braunwald E, PI-T Investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the prove it-timi 22 study. J Am Coll Cardiol. 2006;47:2326–31.View ArticlePubMedGoogle Scholar
- Ramos R, Garcia-Gil M, Comas-Cufi M, Quesada M, Marrugat J, Elosua R, Sala J, Grau M, Marti R, Ponjoan A, Alves-Cabratosa L, Blanch J, Bolibar B. Statins for prevention of cardiovascular events in a low-risk population with low ankle brachial index. J Am Coll Cardiol. 2016;67:630–40.View ArticlePubMedGoogle Scholar
- Parati G, Stergiou G, O'Brien E, Asmar R, Beilin L, Bilo G, Clement D, de la Sierra A, de Leeuw P, Dolan E, Fagard R, Graves J, Head GA, Imai Y, Kario K, Lurbe E, Mallion JM, Mancia G, Mengden T, Myers M, Ogedegbe G, Ohkubo T, Omboni S, Palatini P, Redon J, Ruilope LM, Shennan A, Staessen JA, vanMontfrans G, Verdecchia P, Waeber B, Wang J, Zanchetti A, Zhang Y, European Society of Hypertension Working Group on Blood Pressure M, Cardiovascular V. European society of hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32:1359–66.View ArticlePubMedGoogle Scholar
- American Diabetes A. Standards of medical care in diabetes-2015 abridged for primary care providers. Clin Diab. 2015;33:97–111.View ArticleGoogle Scholar
- Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011;107:1796–801.View ArticlePubMedGoogle Scholar
- Tao H, Wang Y, Zhou X, Zhong W, Zhou H, Li K, Zhao B. Angiographic correlation and synergistic effect of coronary artery stenosis and cerebral artery stenosis: A retrospective study. Med Sci Monit. 2014;20:1902–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Rhoades DA, Welty TK, Wang W, Yeh F, Devereux RB, Fabsitz RR, Lee ET, Howard BV. Aging and the prevalence of cardiovascular disease risk factors in older american indians: The strong heart study. J Am Geriatr Soc. 2007;55:87–94.View ArticlePubMedGoogle Scholar
- Miftahussurur M, Yamaoka Y. Helicobacter pylori virulence genes and host genetic polymorphisms as risk factors for peptic ulcer disease. Expert Rev Gastroenterol Hepatol. 2015;9:1535–47.View ArticlePubMedGoogle Scholar
- Carli DM, Pires RC, Rohde SL, Kavalco CM, Fagundes RB. Peptic ulcer frequency differences related to h. Pylori or aines. Arq Gastroenterol. 2015;52:46–9.View ArticlePubMedGoogle Scholar
- Zhang L, Wu WK, Gallo RL, Fang EF, Hu W, Ling TK, Shen J, Chan RL, Lu L, Luo XM, Li MX, Chan KM, Yu J, Wong VW, Ng SC, Wong SH, Chan FK, Sung JJ, Chan MT, Cho CH. Critical role of antimicrobial peptide cathelicidin for controlling helicobacter pylori survival and infection. J Immunol. 2016;196:1799–809.View ArticlePubMedGoogle Scholar